2025
Osman AM, Remsik J, Snyder J, Wijetunga NA, Manoranjan B, Nobre AR, Freret M, Guber D, Chabot K, Piedrafita-Ortiz S, et al., (2025) Autocrine CXCL1-CXCR2 Signaling Mediates Leptomeningeal Resistance to Radiation Therapy. bioRxiv [Preprint]. doi: 10.1101/2025.02.20.639389.PMID: 40060386
Pappas K, Ferrari M, Smith P, Nandakumar S, Khan Z, Young SB, et al., (2025) BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function. Proc Natl Acad Sci. doi: 10.1073/pnas.2426743122. Epub 2025 Jun 3. PMID: 40460119
2024
Tang C, Castillon VJ, et al., (2024) Obesity-dependent selection of driver mutations in cancer. Nature Genetics. PMID: 38260500. doi:10.1038/s41588-024-01969-3
Tong X, Remsik J, Brook J, Petrova B, Xu L, Li MJ, Snyder J, Chabot K, Estrera R, Osei-Gyening I, Nobre AR, Wang H, Osman AM, Wong AYL, Sidharta M, Piedrafita-Ortiz S, et al., (2024) Retinoid X Receptor Signaling Mediates Cancer Cell Lipid Metabolism in the Leptomeninges. bioRxiv [Preprint] doi: 10.1101/2024.10.13.618083.PMID: 39464048
Xiao X, Fay A, Santos Molina P, et al., (2024) Structure of the M. tuberculosis DnaK−GrpE complex reveals how key DnaK roles are controlled. Nature Communications. PMID: 38253530. doi: 0.1038/s41467-024-44933-9
Waarts MR, Mowla S, Boileau M, Martinez Benitez AR, Sango J, Bagish M, Fernandez-Maestre I, Shan Y, Eisman SE, Park YC, Wereski M, Csete I, O’Connor K, Romero-Vega AC, et al., (2024) CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells. Cancer Discoveries. PMID: 38819218. doi: 10.1158/2159-8290.CD-23-1092
Zhu Y, Pei X, Novaj A, Setton J, Bronder D, Derakhshan F, Selenica P, McDermott N, Orman M, Plum S, et al., (2024) Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors. Genome Medicine. PMID 39198848. doi: 10.1186/s13073-024-01371-y
2023
Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, et al., (2023) Pan-KRAS inhibitor disables oncogenic signaling and tumor growth. Nature. PMID: 37258666. doi: 10.1038/s41586-023-06123-3
Schulze CJ, Seamon KJ, Zhao Y, Ayala-Santos CI, et al., (2023) Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. PMID: 37590355. doi: 10.1126/science.adg9652